Thus, GLP-1 receptor agonists and inhibitors of GLP-1 hydrolysis are now front-line therapies for type 2 diabetes (T2D) (Campbell and Drucker, 2013; Nauck, 2011), and PYY and OXM analogues, which regulate appetite and control energy expenditure, are both currently being developed to treat obesity. This evidence concerns the gene GCG and type 2 diabetes mellitus.